Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by (1,079)

Items 301–400 of 1,079

1. Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting
   John C. Sok, Francesca M Coppelli, Sufi Mary Thomas, Miriam N. Lango, Sichuan Xi, Jennifer Leigh Hunt, Maria L. Freilino, Michael W. Graner, Carol J. Wikstrand, Darell D. Bigner et al. · 2006 · Clinical Cancer Research
2. Building the foundation for genomics in precision medicine
   Samuel Aronson, Heidi L. Rehm · 2015 · Nature
3. The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers
   Masaki Tokumo, Shinichi Toyooka, Katsuyuki Kiura, Hisayuki Shigematsu, Kunitoshi Tomii, Motoi Aoe, Kouichi Ichimura, Toshihide Tsuda, Masaaki Yano, Kazunori Tsukuda et al. · 2005 · Clinical Cancer Research
4. Intratumor Heterogeneity: Seeing the Wood for the Trees
   Timothy Anthony Yap, Marco Gerlinger, P. Andrew Futreal, Lajos Pusztai, Charles Swanton · 2012 · Science Translational Medicine
5. Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
   Jose M Baselga, José Manuel Trigo, Jean Bourhis, Jacques Tortochaux, H. Cortés-Funes, Ricardo Hitt, Pere Gascón, Nadia Amellal, Andreas Harstrick, André Michael Eckardt · 2005 · Journal of Clinical Oncology
6. Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
   Monica Kong-Beltran, Somasekar Seshagiri, Jiping Zha, Wenjing Zhu, Kaumudi M. Bhawe, Nerissa Mendoza, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Ling Fu et al. · 2006 · Cancer Research
7. New and emerging targeted treatments in advanced non-small-cell lung cancer
   Fred R. Hirsch, Kenichi Suda, Jacinta Wiens, Paul A. Bunn · 2016 · The Lancet
8. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
   Gromoslaw Aleksander Smolen, Raffaella Sordella, Beth Muir, Gayatry Mohapatra, Anne Barmettler, Heidi Archibald, Woo Jae Kim, Ross A. Okimoto, Daphne W. Bell, Dennis C. Sgroi et al. · 2006 · Proceedings of the National Academy of Sciences
9. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
   Young Seok Ju, Won‐Chul Lee, Jong-Yeon Shin, Seungbok Lee, Thomas Bleazard, Jae‐Kyung Won, Young Tae Kim, Jong‐Il Kim, Jin Hyoung Kang, Jeong‐Sun Seo · 2011 · Genome Research
10. Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
    Roman Perez-Soler, Leonard B. Saltz · 2005 · Journal of Clinical Oncology
11. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
    Alice Tsang Shaw, Luc Friboulet, Ignaty Leshchiner, Justin F. Gainor, Simon Bergqvist, Alexei Brooun, Benjamin J. Burke, Ya‐Li Deng, Wei Liu, Leila Dardaei et al. · 2015 · New England Journal of Medicine
12. Mechanisms of resistance to EGFR-targeted drugs: lung cancer
    Morgillo, Floriana, Della Corte, Carminia Maria, Fasano, Morena, Ciardiello, Fortunato · 2016 · ESMO Open
13. Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
    Peter S. Hammerman, Martin L. Sos, Alex H. Ramos, Chunxiao Xu, Amit Dutt, Wenjun Zhou, Lear E. Brace, Brittany A. Woods, Wenchu Lin, Jianming Zhang et al. · 2011 · Cancer Discovery
14. Targeting Tyrosine Kinases in Cancer: The Second Wave
    Jose M Baselga · 2006 · Science
15. Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225
    Grant A. McArthur, George D. Demetri, Allan van Oosterom, Michael Charles Heinrich, Maria Dêbiec‐Rychter, Christopher L. Corless, Zariana G. Nikolova, Saša Dimitrijević, Jonathan Alfred Fletcher · 2005 · Journal of Clinical Oncology
16. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
    McMillin, Douglas W., Negri, Joseph M., Mitsiades, Constantine S. · 2013 · Nature Reviews Drug Discovery
17. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
    Garassino, Marina Chiara, Martelli, Olga, Broggini, Massimo, Farina, Gabriella, Veronese, Silvio, Rulli, Eliana, Bianchi, Filippo, Bettini, Anna, Longo, Flavia, Moscetti, Luca et al. · 2013 · The Lancet Oncology
18. Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors
    Politi, Katerina, Zakowski, Maureen F., Fan, Pang-Dian, Schonfeld, Emily A., Pao, William, Varmus, Harold E. · 2006 · Genes & Development
19. Epidemiology of Lung Cancer: Looking to the Future
    Anthony J. Alberg, Malcolm V. Brock, Jonathan M. Samet · 2005 · Journal of Clinical Oncology
20. The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
    M. A. Lemmon, Mark A. Lemmon, K. M. Ferguson · 2014 · Cold Spring Harbor Perspectives in Biology
21. A robustness-based approach to systems-oriented drug design
    Kitano, Hiroaki · 2007 · Nature Reviews Drug Discovery
22. Lung cancer: New biological insights and recent therapeutic advances
    Suresh S. Ramalingam, Taofeek Kunle Owonikoko, Fadlo Raja Khuri · 2011 · CA A Cancer Journal for Clinicians
23. Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance
    Kimmo J. Hatanpaa, Sandeep Burma, Dawen Zhao, Amyn A. Habib · 2010 · Neoplasia
24. <i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
    Arcila, Maria E., Nafa, Khedoudja, Chaft, Jamie E., Rekhtman, Natasha, Lau, Christopher, Reva, Boris A., Zakowski, Maureen F., Kris, Mark G., Ladanyi, Marc · 2013 · Molecular Cancer Therapeutics
25. Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer
    Helen Ruth Davies, Chris Hunter, Raffaella Smith, Philip Stephens, Chris Greenman, Graham R. Bignell, Jon W. Teague, Adam P. Butler, Sarah Edkins, Claire Stevens et al. · 2005 · Cancer Research
26. EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
    Kentaro Inamura, Kengo Takeuchi, Yuki Togashi, Kimie Nomura, Hironori Ninomiya, Michiyo Okui, Yukitoshi Satoh, Sakae Okumura, Ken Nakagawa, Manabu Soda et al. · 2008 · Journal of Thoracic Oncology
27. Regulation of MAPKs by growth factors and receptor tyrosine kinases
    Menachem Katz, Ido Amit, Yosef Yarden · 2007 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
28. Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
    Qiang Ma, Anthony Y.H. Lu · 2011 · Pharmacological Reviews
29. Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
    Kurtis D. Davies, Anh Tuan Le, Mariana F. Theodoro, Margaret C. Skokan, Dara L. Aisner, Eamon M. Berge, Luigi Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo G. Roncalli et al. · 2012 · Clinical Cancer Research
30. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
    Ohashi, Kadoaki, Maruvka, Yosef E., Michor, Franziska, Pao, William · 2013 · Journal of Clinical Oncology
31. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
    Haas-Kogan, Daphne A., Prados, Michael D., Tihan, Tarik, Eberhard, David A., Jelluma, Nannette, Arvold, Nils D., Baumber, Rachel, Lamborn, Kathleen R., Kapadia, Ami, Malec, Mary et al. · 2005 · JNCI Journal of the National Cancer Institute
32. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
    Jhawer, Minaxi, Goel, Sanjay, Wilson, Andrew J., Montagna, Cristina, Ling, Yi-He, Byun, Do-Sun, Nasser, Shannon, Arango, Diego, Shin, Joongho, Klampfer, Lidija et al. · 2008 · Cancer Research
33. Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
    Robichaux, Jacqulyne P., Elamin, Yasir Y., Tan, Zhi, Carter, Brett W., Zhang, Shuxing, Liu, Shengwu, Li, Shuai, Chen, Ting, Poteete, Alissa, Estrada-Bernal, Adriana et al. · 2018 · Nature Medicine
34. Recent advances in the management of lung cancer
    Gavin S. Jones, David Baldwin · 2018 · Clinical Medicine
35. Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
    Philip A. Philip, Michelle R. Mahoney, Cristine Allmer, James Phillip Thomas, Henry Clement Pitot, George Kim, Ross C. Donehower, Tom R. Fitch, Joel Picus, Charles Erlichman · 2005 · Journal of Clinical Oncology
36. Impact of EGFR expression on colorectal cancer patient prognosis and survival
    Jean‐Philippe Spano, Christine Lagorce, Dan Atlan, Gerard Alain Milano, Julien Dômont, Robert Benamouzig, Alain Attar, Joseph Bénichou, Antoine Martin, Jean‐François Morère et al. · 2004 · Annals of Oncology
37. DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer
    Zhong Zheng, Tingan Chen, Xueli Li, Eric B. Haura, Anupama Sharma, Gerold Bepler · 2007 · New England Journal of Medicine
38. Multiscale Cancer Modeling
    Thomas S. Deisboeck, Zhihui Wang, Paul Macklin, Vittorio Cristini C · 2011 · Annual Review of Biomedical Engineering
39. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
    J. A. Engelman, Toru Mukohara, Kreshnik Zejnullahu, Eugene Lifshits, Ana M. Borras, Christopher-Michael Gale, George N. Naumov, Beow Yong Yeap, E. Jarrell, J. Sun et al. · 2006 · Journal of Clinical Investigation
40. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
    Neal Ian Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Đačić, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan‐Sebastian Saldivar, Jeremy Andrew Squire et al. · 2013 · Journal of Molecular Diagnostics
41. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients
    Ni, Xiaohui, Zhuo, Minglei, Su, Zhe, Duan, Jianchun, Gao, Yan, Wang, Zhijie, Zong, Chenghang, Bai, Hua, Chapman, Alec R., Zhao, Jun et al. · 2013 · Proceedings of the National Academy of Sciences
42. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
    Leko, Vid, Rosenberg, Steven A. · 2020 · Cancer Cell
43. Challenges and Opportunities in Cancer Drug Resistance
    Richard A. Ward, Stephen E. Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, Paul D. Smith · 2020 · Chemical Reviews
44. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.
    Gillian C. Bethune, Drew C.G. Bethune, Neale D. Ridgway, Zhaolin Xu · 2010 · Europe PMC (PubMed Central)
45. Presence ofEpidermal Growth Factor ReceptorGene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer
    Michio Inukai, Shinichi Toyooka, Sachio Ito, Hiroaki Asano, Shuji Ichihara, Junichi Soh, Hiroshi Suehisa, Mamoru Ouchida, Keisuke Aoe, Motoi Aoe et al. · 2006 · Cancer Research
46. Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
    Lynch, Thomas J., Patel, Taral, Dreisbach, Luke, McCleod, Michael, Heim, William J., Hermann, Robert C., Paschold, Eugene, Iannotti, Nicholas O., Dakhil, Shaker, Gorton, Steven et al. · 2010 · Journal of Clinical Oncology
47. FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
    Martin H. Cohen, John R. Johnson, Yeh‐Fong Chen, Rajeshwari Sridhara, Richard Pazdur · 2005 · The Oncologist
48. PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
    Filip Jankú, Jennifer J. Wheler, Shannon Neville Westin, Stacy Moulder, Aung Naing, Apostolia Maria Tsimberidou, Siqing Fu, Gerald Steven Falchook, David S. Hong, Ignacio Garrido‐Laguna et al. · 2012 · Journal of Clinical Oncology
49. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
    Jennifer L. Hsu, Mien‐Chie Hung · 2016 · Cancer and Metastasis Reviews
50. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
    Ji, Hongbin, Li, Danan, Chen, Liang, Shimamura, Takeshi, Kobayashi, Susumu, McNamara, Kate, Mahmood, Umar, Mitchell, Albert, Sun, Yangping, Al-Hashem, Ruqayyah et al. · 2006 · Cancer Cell
51. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset
    Kentaro Inamura, Kengo Takeuchi, Yuki Togashi, Satoko Hatano, Hironori Ninomiya, Noriko Motoi, Mingyon Mun, Yukinori Sakao, Sakae Okumura, Ken Nakagawa et al. · 2009 · Modern Pathology
52. Brain malignancies: Glioblastoma and brain metastases
    Tamara T. Lah, Metka Novak, Barbara Breznik · 2019 · Seminars in Cancer Biology
53. Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib
    Carey, Kendall D., Garton, Andrew J., Romero, Maria S., Kahler, Jennifer, Thomson, Stuart, Ross, Sarajane, Park, Frances, Haley, John D., Gibson, Neil, Sliwkowski, Mark X. · 2006 · Cancer Research
54. EGFR Signaling and Drug Discovery
    Georg Lurje, Heinz‐Josef Lenz · 2009 · Oncology
55. How basal are triple‐negative breast cancers?
    François Bertucci, Pascal Finetti, Nathalie Cervera, Benjamin Esterni, Fabienne Hermitte, Patrice Viens, Daniel Birnbaum · 2008 · International Journal of Cancer
56. Oncogene addiction: setting the stage for molecularly targeted cancer therapy
    Sreenath V. Sharma, Jeffrey E. Settleman · 2007 · Genes & Development
57. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i>
    Ohashi, Kadoaki, Sequist, Lecia V., Arcila, Maria E., Moran, Teresa, Chmielecki, Juliann, Lin, Ya-Lun, Pan, Yumei, Wang, Lu, de Stanchina, Elisa, Shien, Kazuhiko et al. · 2012 · Proceedings of the National Academy of Sciences
58. Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non–Small Cell Lung Cancer
    Young Lim Choi, Kengo Takeuchi, Manabu Soda, Kentaro Inamura, Yuki Togashi, Satoko Hatano, Munehiro Enomoto, Toru Hamada, Hidenori Haruta, Hideki Watanabe et al. · 2008 · Cancer Research
59. The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
    Josep M. Tabernero · 2007 · Molecular Cancer Research
60. Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
    Nguyen, Kim-Son H., Kobayashi, Susumu, Costa, Daniel B. · 2009 · Clinical Lung Cancer
61. Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer
    Joseph M. Amann, Shailaja Kalyankrishna, Pierre P. Massion, Joyce Ellen Ohm, Luc Girard, Hisayuki Shigematsu, Michael Peyton, Denise M. Juroske, Yuhui Huang, J. Stuart Salmon et al. · 2005 · Cancer Research
62. Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
    Laura E. MacConaill, Catarina D. Campbell, Sarah M. Kehoe, Adam Joel Bass, Charlie Hatton, Lili Niu, Matt Davis, Keluo Yao, Megan Hanna, Chandrani Mondal et al. · 2009 · PLoS ONE
63. Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
    Keiichi Ota, Koichi Azuma, Akihiko Kawahara, Satoshi Hattori, Eiji Iwama, Junko Tanizaki, Taishi Harada, Koichiro Matsumoto, Koichi Takayama, Shinzo Takamori et al. · 2015 · Clinical Cancer Research
64. Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients
    Akihiko Yoshizawa, Shinji Sumiyoshi, Makoto Sonobe, Masashi Kobayashi, Masakazu Fujimoto, Fumi Kawakami, Tatsuaki Tsuruyama, William David Travis, Hiroshi Date, Hironori Haga · 2012 · Journal of Thoracic Oncology
65. Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
    Lecia Van Dam Sequist, Benjamin Besse, Thomas James Lynch, Vincent A. Miller, Kwok‐Kin Wong, Barbara Jennifer Gitlitz, Keith D. Eaton, Charles Zacharchuk, Amy Freyman, Christine Powell et al. · 2010 · Journal of Clinical Oncology
66. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience
    Sholl, Lynette M., Aisner, Dara L., Varella-Garcia, Marileila, Berry, Lynne D., Dias-Santagata, Dora, Wistuba, Ignacio I., Chen, Heidi, Fujimoto, Junya, Kugler, Kelly, Franklin, Wilbur A. et al. · 2015 · Journal of Thoracic Oncology
67. Epidermal growth factor receptor inhibition strategies in oncology
    Harari, P M · 2004 · Endocrine-Related Cancer
68. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
    Llovet, Josep M., Villanueva, Augusto, Marrero, Jorge A., Schwartz, Myron, Meyer, Tim, Galle, Peter R., Lencioni, Riccardo, Greten, Tim F., Kudo, Masatoshi, Mandrekar, Sumithra J. et al. · 2021 · Hepatology
69. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
    Neal Ian Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Đačić, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan‐Sebastian Saldivar, Jeremy Andrew Squire et al. · 2013 · Archives of Pathology & Laboratory Medicine
70. A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
    Mari A. Mino-Kenudson, Lucian R. Chirieac, Kenny Law, Jason L. Hornick, Neal Ian Lindeman, Eugene Jerome Mark, David Cohen, Bruce Evan Johnson, Pasi Antero Janne, Anthony John Iafrate et al. · 2010 · Clinical Cancer Research
71. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
    Yuankai Shi, Li Zhang, Xiaoqing Liu, Caicun Zhou, Li Zhang, Shucai Zhang, Dong Wang, Qiang Li, Shukui Qin, Chunhong Hu et al. · 2013 · The Lancet Oncology
72. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
    Marco Gerlinger, Charles Swanton · 2010 · British Journal of Cancer
73. Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1
    Mark Magdi Awad, Ryohei Katayama, Michele A. McTigue, Wei Liu, Ya-Li Deng, Alexei Brooun, Luc Friboulet, Donghui Huang, Matthew D. Falk, Sergei L. Timofeevski et al. · 2013 · New England Journal of Medicine
74. Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
    Vince D. Cataldo, Don Lynn Gibbons, Roman Perez-Soler, Alfonso Quintás‐Cardama · 2011 · New England Journal of Medicine
75. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
    Kobayashi, Yoshihisa, Mitsudomi, Tetsuya · 2016 · Cancer Science
76. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
    Douillard, J-Y, Ostoros, G, Cobo, M, Ciuleanu, T, McCormack, R, Webster, A, Milenkova, T · 2014 · British Journal of Cancer
77. New prognostic factors and scoring system for patients with skeletal metastasis
    Hirohisa Katagiri, Rieko Okada, Tatsuya Takagi, Mitsuru Takahashi, Hideki Murata, Hideyuki Harada, Tetsuo Nishimura, Hirofumi Asakura, Hirofumi Ogawa · 2014 · Cancer Medicine
78. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity
    Urs Meyer · 2004 · Nature Reviews Genetics
79. An In vivo Platform for Translational Drug Development in Pancreatic Cancer
    Belén Rubio‐Viqueira, Antonio Jimeno, George Cusatis, Xianfeng Zhang, Christine A. Iacobuzio–Donahue, Collins A. Karikari, Chanjusn Shi, Kathleen D. Danenberg, Peter V. Danenberg, Hidekazu Kuramochi et al. · 2006 · Clinical Cancer Research
80. Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
    Jose M Baselga, Joan Albanell, Amparo Ruı́z, Ana M. Lluch, Pere Gascón, Vicente Guillém, Sonia González, Sílvia Sauleda, Irene Marimón, Josep M. Tabernero et al. · 2005 · Journal of Clinical Oncology
81. Cyclin D1 in Breast Cancer Pathogenesis
    Andrew Arnold, Αλέξανδρος Παπανικολάου · 2005 · Journal of Clinical Oncology
82. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
    James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su, Te‐Chun Hsia, Chun‐Ming Tsai, Sai‐Hong Ignatius Ou, Chong‐Jen Yu, Gee‐Chen Chang, Ching‐Liang Ho, Lecia Van Dam Sequist et al. · 2012 · The Lancet Oncology
83. Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials
    Rubinstein, Lawrence V., Korn, Edward L., Freidlin, Boris, Hunsberger, Sally, Ivy, S. Percy, Smith, Malcolm A. · 2005 · Journal of Clinical Oncology
84. Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology
    Pasi Antero Janne, Jeffrey A. Engelman, Bruce Evan Johnson · 2005 · Journal of Clinical Oncology
85. A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
    Manuel M. Hidalgo, Elizabeth M. Bruckheimer, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Elizabeth De Oliveira, Belén Rubio‐Viqueira, Steven J. Strawn, Michael J. Wick, James Martell, David Sidransky · 2011 · Molecular Cancer Therapeutics
86. Epidermal Growth Factor Receptor Copy Number Alterations Correlate With Poor Clinical Outcome in Patients With Head and Neck Squamous Cancer
    Stéphane Temam, Hidetoshi Kawaguchi, Adel K. El‐Naggar, Jaroslav Jelı́nek, Hongli Tang, Diane D. Liu, Wenhua Lang, Jean‐Pierre J. Issa, J. Jack Lee, Li Mao · 2007 · Journal of Clinical Oncology
87. Gefitinib — a novel targeted approach to treating cancer
    Roy S. Herbst, Masahiro Fukuoka, Jose M Baselga · 2004 · Nature reviews. Cancer
88. Classification and Pathology of Lung Cancer
    Min Zheng · 2016 · Surgical Oncology Clinics of North America
89. Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features
    Issan Yee San Tam, Lap-Ping Chung, WS Suen, Elaine Wang, May Chun Mei Wong, Kok Keung Ho, Wah Kit Lam, Shui Wah Chiu, Luc Girard, John Dorrance Minna et al. · 2006 · Clinical Cancer Research
90. The EGF receptor family: spearheading a merger of signaling and therapeutics
    Erez M. Bublil, Yosef Yarden · 2007 · Current Opinion in Cell Biology
91. Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
    Gerlinde Wernig, Michael G. Kharas, Rachel O. Okabe, Sandra A. Moore, Dena S. Leeman, Dana E. Cullen, Maricel C. Gozo, Elizabeth P. McDowell, Ross L. Levine, John Doukas et al. · 2008 · Cancer Cell
92. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
    Dora C. Dias-Santagata, Sara Akhavanfard, Serena S. David, Kathy Vernovsky, Georgiana Kuhlmann, Susan L. Boisvert, Hannah Stubbs, Ultan McDermott, Jeffrey E. Settleman, Eunice Lee Kwak et al. · 2010 · EMBO Molecular Medicine
93. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer
    Welsh, James W., Komaki, Ritsuko, Amini, Arya, Munsell, Mark F., Unger, Wyatt, Allen, Pamela K., Chang, Joe Y., Wefel, Jeffrey S., McGovern, Susan L., Garland, Linda L. et al. · 2013 · Journal of Clinical Oncology
94. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
    Satoshi Watanabe, Junta Tanaka, Takeshi Ota, Rie Kondo, Hiroshi Tanaka, Hiroshi Kagamu, Kosuke Ichikawa, Jun Koshio, Junko Baba, Takao Miyabayashi et al. · 2011 · BMC Cancer
95. Endocytosis and Cancer
    Ira Mellman, Yosef Yarden · 2013 · Cold Spring Harbor Perspectives in Biology
96. Overview of current systemic management of EGFR-mutant NSCLC
    W.-H. Hsu, James Chih‐Hsin Yang, Tony S.K. Mok, Herbert Ho-Fung Loong · 2017 · Annals of Oncology
97. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
    Roy S. Herbst, Rafat Ansari, Frederique Bustin, Patrick J. Flynn, Lowell L. Hart, Gregory A. Otterson, Gordana Vlahovic, Chang-Heok Soh, Paula G. O’Connor, John Daniel Hainsworth · 2011 · The Lancet
98. TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
    Yao, Zhan, Fenoglio, Silvia, Gao, Ding Cheng, Camiolo, Matthew, Stiles, Brendon, Lindsted, Trine, Schlederer, Michaela, Johns, Chris, Altorki, Nasser, Mittal, Vivek et al. · 2010 · Proceedings of the National Academy of Sciences
99. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
    Xie, Xin, Yu, Tingting, Li, Xiang, Zhang, Nan, Foster, Leonard J., Peng, Cheng, Huang, Wei, He, Gu · 2023 · Signal Transduction and Targeted Therapy
100. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
     Chee‐Seng Tan, David Gilligan, Simon Pacey · 2015 · The Lancet Oncology